Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (91-100 of 164) with videos related to

Pageof 17
Sort By:
Cancer|October 4, 2021
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional studyVirginie Nerich, Christophe Guyeux, Michel Henry-Amar, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
British Journal of Haematology|April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA groupCharles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working groupDamien Roos-Weil, Florence Nguyen-Khac, Sylvie Chevret, et al.
American Journal of Hematology|February 5, 2025
Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative StudyAnne Beatrice Notarantonio, Stéphane Morisset, Romain Piucco, et al.
Clinical Hematology International|July 25, 2024
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emergeOlivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, et al.
American Journal of Hematology|July 24, 2023
Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trialAnne Béatrice Notarantonio, Maud D'aveni-Piney, Simona Pagliuca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.
Blood Advances|July 17, 2020
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE studyMarie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, et al.
American Journal of Hematology|April 28, 2021
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapyRémy Duléry, Sylvain Lamure, Marc Delord, et al.
Pageof 17

Showing results (91-100 of 164) with videos related to

Sort By:
Pageof 17
Cancer|October 4, 2021
Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional studyVirginie Nerich, Christophe Guyeux, Michel Henry-Amar, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
British Journal of Haematology|April 26, 2025
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA groupCharles Herbaux, Emmanuel Bachy, Reda Bouabdallah, et al.
Genes, Chromosomes & Cancer|September 12, 2018
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working groupDamien Roos-Weil, Florence Nguyen-Khac, Sylvie Chevret, et al.
American Journal of Hematology|February 5, 2025
Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative StudyAnne Beatrice Notarantonio, Stéphane Morisset, Romain Piucco, et al.
Clinical Hematology International|July 25, 2024
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emergeOlivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, et al.
American Journal of Hematology|July 24, 2023
Systemic complement activation influences outcomes after allogeneic hematopoietic cell transplantation: A prospective French multicenter trialAnne Béatrice Notarantonio, Maud D'aveni-Piney, Simona Pagliuca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2019
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C Kluin-Nelemans, Eva Hoster, Olivier Hermine, et al.
Blood Advances|July 17, 2020
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE studyMarie-Helene Delfau-Larue, Marie-Laure Boulland, Asma Beldi-Ferchiou, et al.
American Journal of Hematology|April 28, 2021
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapyRémy Duléry, Sylvain Lamure, Marc Delord, et al.
Pageof 17